Rezolute Announces Presentation at the 60th Annual ESPE Meeting
07 sept. 2022 07h00 HE
|
Rezolute, Inc.
Data from Phase 2b RIZE Study in congenital hyperinsulinism will be presented in oral presentation REDWOOD CITY, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a...
Rezolute Announces Promotion of Brian Roberts, M.D. to Chief Medical Officer
01 juin 2022 07h00 HE
|
Rezolute, Inc.
REDWOOD CITY, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential...
Rezolute Reports Third Quarter Fiscal 2022 Financial Results and Highlights Company Progress
12 mai 2022 16h05 HE
|
Rezolute, Inc.
Announced a $130 million registered direct offering and concurrent private placement Positive topline results from Phase 2b RIZE study of RZ358 exceeded expectations and demonstrated highly...
Rezolute to Host Corporate Update Call on May 4, 2022
04 mai 2022 16h01 HE
|
Rezolute, Inc.
REDWOOD CITY, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential...
Rezolute, Inc. Announces Closing of Registered Direct Offering
04 mai 2022 09h33 HE
|
Rezolute, Inc.
REDWOOD CITY, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential...
Rezolute, Inc. Announces Aggregate $130 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
01 mai 2022 23h25 HE
|
Rezolute, Inc.
REDWOOD CITY, Calif., May 01, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential...
Rezolute Announces Positive Data from its Phase 2b (RIZE) Study of RZ358 in Patients with Congenital Hyperinsulinism
01 mai 2022 14h00 HE
|
Rezolute, Inc.
Highly significant ~75% reduction in hypoglycemia events at anticipated therapeutic doses≥50% improvement in hypoglycemia in 100% of patients in high-dose cohort, with no adverse drug reactions or...
RZ358 Phase 2b (RIZE Study) Topline Data to be Unveiled at Pediatric Endocrine Society Annual Meeting on May 1, 2022
26 avr. 2022 16h05 HE
|
Rezolute, Inc.
Rezolute to host conference call presentation and discussion of the data on Sunday, May 1 at 2:30 p.m. ET REDWOOD CITY, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a...
Rezolute Joins the Rare Disease Company Coalition
29 mars 2022 07h00 HE
|
Rezolute, Inc.
REDWOOD CITY, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential...
Rezolute Announces Positive Results from the Phase 2b RIZE Study of RZ358 in Congenital Hyperinsulinism
23 mars 2022 07h00 HE
|
Rezolute, Inc.
The RIZE study demonstrated highly significant improvements in hypoglycemia and good safety and tolerability Results to be presented in an oral presentation at a medical congress in 2Q 2022 REDWOOD...